Opiate receptors grow back pet/mri hybrid
The primary focus of this review is on functional PET/MRI studies of neurotransmitter and receptor systems, with an emphasis on the dopamine, opioid, serotonin..
A pharmacological imaging challenge based on 11C-buprenorphine PET-MRI to explore the response to opioids in humans
Access this article
Log in via an institution
Subscribe and save
Springer+ Basic
€32.70 /Month
- Get 10 units per month
- Download Article/Chapter or eBook
- 1 Unit = 1 Article or 1 Chapter
- Cancel anytime
Buy Now
Price includes VAT (Ukraine)
Instant access to the full article PDF.
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
References
Auvity S, Goutal S, Caillé F, Vodovar D, Pruvost A, Wimberley C, et al.
Pharmacokinetic neuroimaging to study the dose-related brain kinetics and target engagement of buprenorphine in vivo.
Since the late s, the advent of hybrid PET-MRI Mu- and kappa-opioid receptors are recognized as potential targets for treating depression.
- Since the late s, the advent of hybrid PET-MRI Mu- and kappa-opioid receptors are recognized as potential targets for treating depression.
- This paper reviews the methodologic improvements and potential neurologic and psychiatric applications of this novel technology.
- The primary focus of this review is on functional PET/MRI studies of neurotransmitter and receptor systems, with an emphasis on the dopamine, opioid, serotonin.
- Opioids bind to opioid receptors in the brain, spinal cord, and other sites, activating analgesic and reward pathways It is important to.
- Future neuroreceptor PET/MRI research activities should also involve studying the opioid system and its effect on brain haemodynamics, e.g.
Upadhyay J, Anderson J, Schwarz AJ, Coimbra A, Baumgartner R, Pendse G, et al. Imaging drugs with
Neuropsychopharmacology. 2021;46:1220–8.
ArticleCASPubMedPubMed Central Google Scholar